摘要
目的探讨单用乌梅方加减治疗溃疡性结肠炎的安全性和有效性。方法纳入乌梅方加减与单用西药治疗溃疡性结肠炎的随机对照试验,用Cochrane方法评价文献的质量;对疗效（临床疗效、复发率）和不良反应进行Meta分析。结果共纳入12篇随机对照试验文献,隐蔽、盲法和意向性分析等方面存在不足,均为低质量文献。与单用西药对比,乌梅方加减的临床疗效的RR值为1.17（95%CI为1.10-1.24）,差异有统计学意义（P〈0.05）。两组复发率、不良反应发生率的差异均有统计学意义（P〈0.05）,RR分别为0.19和0.22。漏斗图分析显示不存在发表偏倚。结论与单用西药对比,乌梅方治疗溃疡性结肠炎的临床疗效更好,复发率更低,且具有良好的安全性。本研究纳入文献的偏倚较多,需要高质量的随机对照试验支持。
Objective To investigate the safety and efficacy of modified Wumei（Fructus Pruni Mume）Prescription in the treatment of ulcerative colitis.Methods The randomized controlled trials（RCTs）of modified Wumei Prescription versus Western medicine for ulcerative colitis were included.The quality of RCTs was assessed using the Cochrane method.The included RCTs were subjected to meta-analysis to investigate the efficacy（clinical outcome and recurrence rate）and adverse events.Results A total of 12 RCTs were included in the analysis.The quality of included RCTs was low due to the deficiency in concealment,blind method,and intentional analysis.Compared with the Western medicine group,the modified Wumei Prescription group had a significantly better clinical outcome（risk ratio RR=1.17,95% CI：1.10-1.24,P〈0.05）.There were significant differences in recurrence rate and the incidence of adverse events between the two groups（RR=0.19and0.22,P〈0.05）.The funnel plots showed no publication bias.Conclusion Compared with Western medicine,modified Wumei Prescription has better clinical efficacy,a lower recurrence rate,and good safety in the treatment of ulcerative colitis.However,the conclusion needs to be supported by high-quality RCTs due to the bias of RCTs included in this meta-analysis.
出处
《安徽中医药大学学报》
2016年第3期92-96,共5页
Journal of Anhui University of Chinese Medicine
基金
国家自然科学基金项目(81403296)
广州中医药大学"青年英才培养工程"资助项目(QNYC20140101)
广东省高等学校优秀青年教师项目(YQ2015041)
